Camlin Fine Sciences Inkomsten in het verleden
Verleden criteriumcontroles 0/6
De winst van Camlin Fine Sciences is gedaald met een gemiddeld jaarlijks percentage van -32.9%, terwijl de winst van de Chemicals -industrie jaarlijks groeide met 6.7%. De inkomsten zijn groeide met een gemiddeld percentage van 7% per jaar.
Belangrijke informatie
-32.91%
Groei van de winst
-36.73%
Groei van de winst per aandeel
| Chemicals Groei van de industrie | 17.68% |
| Inkomstengroei | 7.04% |
| Rendement op eigen vermogen | -1.79% |
| Nettomarge | -0.79% |
| Volgende winstupdate | 26 May 2026 |
Recente prestatie-updates uit het verleden
Recent updates
532834: Upcoming Meetings Will Support Bullish Outlook With Stable Forward Assumptions
Analysts have left the Camlin Fine Sciences price target unchanged at ₹182.5, explaining that a slightly lower discount rate and marginally higher profit margin assumptions are balanced by a modestly lower future P/E input. What's in the News Special and Extraordinary Shareholders Meeting scheduled via postal ballot in India on May 7, 2026, indicating upcoming shareholder decisions that may affect the company structure or capital plans (Key Developments).532834: Upcoming Meetings Will Support Confident Outlook Despite Revised Forecast Assumptions
Analysts have trimmed their price target on Camlin Fine Sciences from ₹235 to ₹182.5. This reflects updated assumptions around fair value, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for Feb 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).532834: Upcoming Results Meeting Will Reinforce Steady Assumptions Supporting Upside Potential
Analysts have kept the fair value estimate for Camlin Fine Sciences steady at ₹235, with only minor tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, resulting in a largely unchanged price target narrative. What's in the News Board meeting scheduled on February 13, 2026 to consider and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).532834: Scheduled Results Review Will Confirm Steady Assumptions Supporting Upside Potential
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹235, citing largely unchanged assumptions around revenue growth, profit margins and future P/E, with only minor tweaks to the discount rate and valuation inputs. What's in the News Board meeting scheduled for February 13, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).532834: Upcoming Results Review Will Support Long Term Upside Potential
Analysts have adjusted their fair value estimate for Camlin Fine Sciences from ₹240 to ₹235, reflecting updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).532834: Upcoming Board And Director Decisions Will Support Long Term Upside
Analysts have maintained their fair value estimate for Camlin Fine Sciences at ₹240.00, with the small adjustments in discount rate and future P/E assumptions reflecting updated views on risk and valuation drivers rather than a change in the headline price target. What's in the News Board meeting scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).532834: Director Reappointment And Steady Assumptions Will Support Long Term Upside
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹240.0 per share, with the unchanged target reflecting consistent assumptions on revenue growth, profit margin and future P/E, alongside a slightly updated discount rate input. What's in the News A board meeting is scheduled for Nov 10, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025, and to discuss other matters (Key Developments).532834: Governance Continuity And Stable Assumptions Will Support Long Term Upside
Analysts have kept their price target for Camlin Fine Sciences steady at ₹240.00. This reflects updated assumptions around a slightly higher discount rate and fine-tuned estimates for revenue growth, profit margin and future P/E, without a clear tilt in either a more optimistic or more cautious direction.532834: Share Swap And Governance Stability Will Drive Long Term Returns
Analysts have maintained their price target for Camlin Fine Sciences at ₹240.00, with only marginal tweaks to the underlying model inputs. This reflects steady confidence in the company’s growth and profitability trajectory.532834: Share Swap Acquisition Will Drive Long Term Returns
Analysts have modestly maintained their outlook on Camlin Fine Sciences, keeping the price target broadly unchanged near ₹240, as small tweaks to the discount rate and forward earnings assumptions continue to support a steady long term growth narrative. What's in the News Board meeting scheduled for November 10, 2025, to approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, and to consider the reappointment of Mahabaleshwar Palekar as a non executive independent director (Key Developments).532834: Share Swap Acquisition And Margin Expansion Will Drive Future Returns
Analysts have lowered their price target for Camlin Fine Sciences from ₹270 to ₹240. They cite updated estimates that reflect improved profit margins and revenue growth, along with a reduced valuation multiple.532834: Acquisition Plan Will Drive Shareholder Value Despite Margin Pressure
Analysts have revised their price target for Camlin Fine Sciences downward from ₹295 to ₹270. They cited lower expected profit margins, even though revenue growth is projected to be stronger.Tariff Benefits And Safety Trends Will Boost US And Europe
Key Takeaways Plant restarts and easing exceptional expenses are set to improve margins, with structural growth driven by global demand for compliant, high-quality food additives. Favorable trade barriers and China+1 supply diversification position Camlin Fine Sciences for market share gains, margin expansion, and reduced dependence on legacy products.Opbrengsten en kosten
Hoe Camlin Fine Sciences geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Dec 25 | 17,780 | -141 | 2,544 | 0 |
| 30 Sep 25 | 17,517 | 187 | 2,386 | 0 |
| 30 Jun 25 | 17,092 | 825 | 2,262 | 0 |
| 31 Mar 25 | 16,665 | 685 | 2,129 | 0 |
| 31 Dec 24 | 16,540 | -2,155 | 2,470 | 0 |
| 30 Sep 24 | 16,064 | -2,231 | 2,406 | 0 |
| 30 Jun 24 | 15,893 | -1,423 | 2,315 | 0 |
| 31 Mar 24 | 14,539 | 651 | 1,977 | 0 |
| 31 Dec 23 | 16,381 | -8 | 1,931 | 0 |
| 30 Sep 23 | 16,400 | 350 | 1,893 | 0 |
| 30 Jun 23 | 17,174 | 674 | 1,850 | 0 |
| 31 Mar 23 | 16,816 | 577 | 1,823 | 0 |
| 31 Dec 22 | 16,441 | 581 | 1,727 | 0 |
| 30 Sep 22 | 16,371 | 628 | 1,710 | 0 |
| 30 Jun 22 | 14,650 | 442 | 1,666 | 0 |
| 31 Mar 22 | 14,121 | 650 | 1,582 | 0 |
| 31 Dec 21 | 13,495 | 598 | 1,521 | 0 |
| 30 Sep 21 | 12,666 | 465 | 1,436 | 0 |
| 30 Jun 21 | 12,122 | 579 | 1,375 | 0 |
| 31 Mar 21 | 11,871 | 510 | 1,301 | 0 |
| 31 Dec 20 | 11,533 | 394 | 1,312 | 0 |
| 30 Sep 20 | 11,293 | 291 | 1,255 | 0 |
| 30 Jun 20 | 10,948 | 302 | 1,207 | 0 |
| 31 Mar 20 | 10,491 | 303 | 1,180 | 0 |
| 31 Dec 19 | 10,243 | 349 | 1,170 | 0 |
| 30 Sep 19 | 9,918 | 277 | 1,139 | 0 |
| 30 Jun 19 | 9,709 | 221 | 1,121 | 0 |
| 31 Mar 19 | 8,922 | 6 | 1,092 | 0 |
| 31 Dec 18 | 8,523 | -139 | 1,053 | 0 |
| 30 Sep 18 | 8,186 | -222 | 1,016 | 0 |
| 30 Jun 18 | 7,634 | -277 | 969 | 0 |
| 31 Mar 18 | 7,206 | -338 | 935 | 0 |
| 31 Dec 17 | 6,403 | -367 | 865 | 20 |
| 30 Sep 17 | 5,676 | -311 | 843 | 20 |
| 30 Jun 17 | 5,347 | -275 | 820 | 22 |
| 31 Mar 17 | 5,339 | -128 | 820 | 0 |
| 31 Dec 16 | 5,149 | 98 | 737 | 21 |
| 30 Sep 16 | 5,013 | 174 | 649 | 21 |
| 30 Jun 16 | 5,063 | 232 | 496 | 21 |
| 31 Mar 16 | 4,893 | 358 | 562 | 21 |
| 31 Dec 15 | 5,083 | 445 | 879 | 25 |
| 30 Sep 15 | 5,238 | 463 | 906 | 25 |
| 30 Jun 15 | 5,531 | 552 | 883 | 25 |
Kwaliteitswinsten: 532834 is momenteel verliesgevend.
Groeiende winstmarge: 532834 is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 532834 is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 32.9% per jaar.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van 532834 over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: 532834 is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Chemicals industrie ( 10.4% ).
Rendement op eigen vermogen
Hoge ROE: 532834 heeft een negatief Return on Equity ( -1.79% ), omdat het momenteel verliesgevend is.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/22 18:37 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Camlin Fine Sciences Limited wordt gevolgd door 9 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Ankur Periwal | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| Satish Kumar | CGS International |